BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
BriaCell Therapeutics (NASDAQ: BCTX) has announced two clinical data poster presentations at the upcoming ESMO Congress 2025 in Berlin, Germany. The presentations will focus on the company's Phase III pivotal trial of Bria-IMT combined with CPI for advanced metastatic breast cancer treatment.
The two posters (#8212 and #3928) will present data on the BRIA-ABC trial, examining both the pivotal trial results and the feasibility and biomarker validation aspects of this international randomized Phase 3 study. The abstracts will be published on the ESMO website on October 13th, 2025, with the congress taking place from October 17-21, 2025.
BriaCell Therapeutics (NASDAQ: BCTX) ha annunciato la presentazione di due poster con dati clinici al prossimo ESMO Congress 2025 che si terrà a Berlino, Germania. Le presentazioni si concentreranno sullo studio pivotale di Fase III di Bria-IMT in combinazione con CPI per il trattamento del carcinoma mammario metastatico avanzato.
I due poster (#8212 e #3928) mostreranno i dati dello studio BRIA-ABC, analizzando sia i risultati dello studio pivotale sia gli aspetti relativi alla fattibilità e alla validazione dei biomarcatori di questo studio internazionale randomizzato di Fase 3. Gli abstract saranno pubblicati sul sito ESMO il 13 ottobre 2025, mentre il congresso si svolgerà dal 17 al 21 ottobre 2025.
BriaCell Therapeutics (NASDAQ: BCTX) ha anunciado dos presentaciones de pósters con datos clínicos en el próximo Congreso ESMO 2025 en Berlín, Alemania. Las presentaciones se centrarán en el ensayo pivotal de fase III de Bria-IMT combinado con CPI para el tratamiento del cáncer de mama metastásico avanzado.
Los dos pósters (#8212 y #3928) presentarán datos del ensayo BRIA-ABC, examinando tanto los resultados del ensayo pivotal como la viabilidad y validación de biomarcadores de este estudio internacional aleatorizado de fase 3. Los resúmenes se publicarán en la página web de ESMO el 13 de octubre de 2025, y el congreso se celebrará del 17 al 21 de octubre de 2025.
BriaCell Therapeutics (NASDAQ: BCTX)가 독일 베를린에서 열리는 ESMO Congress 2025에서 두 건의 임상 데이터 포스터 발표를 진행할 예정입니다. 발표는 진행성 전이성 유방암 치료를 위한 Bria-IMT와 CPI 병용의 3상 핵심 임상시험에 초점을 맞출 것입니다.
두 포스터(#8212 및 #3928)는 BRIA-ABC 시험 데이터를 발표하며, 핵심 시험 결과와 함께 이 국제 무작위 3상 연구의 타당성 및 바이오마커 검증 측면을 다룰 예정입니다. 초록은 2025년 10월 13일 ESMO 웹사이트에 게시되며, 학회는 2025년 10월 17일부터 21일까지 개최됩니다.
BriaCell Therapeutics (NASDAQ : BCTX) a annoncé la présentation de deux posters de données cliniques lors du prochain Congrès ESMO 2025 à Berlin, en Allemagne. Les présentations porteront sur l'essai pivot de phase III de Bria-IMT combiné avec CPI pour le traitement du cancer du sein métastatique avancé.
Les deux posters (#8212 et #3928) présenteront les données de l'essai BRIA-ABC, examinant à la fois les résultats de l'essai pivot et les aspects de faisabilité et de validation des biomarqueurs de cette étude internationale randomisée de phase 3. Les résumés seront publiés sur le site web de l’ESMO le 13 octobre 2025, le congrès se déroulant du 17 au 21 octobre 2025.
BriaCell Therapeutics (NASDAQ: BCTX) hat zwei klinische Datenposter-Präsentationen auf dem bevorstehenden ESMO Kongress 2025 in Berlin, Deutschland, angekündigt. Die Präsentationen konzentrieren sich auf die Phase-III-Schlüsselstudie von Bria-IMT in Kombination mit CPI zur Behandlung von fortgeschrittenem metastasiertem Brustkrebs.
Die beiden Poster (#8212 und #3928) werden Daten der BRIA-ABC-Studie präsentieren, die sowohl die Ergebnisse der Schlüsselstudie als auch die Machbarkeit und Biomarker-Validierung dieser internationalen randomisierten Phase-3-Studie untersuchen. Die Abstracts werden am 13. Oktober 2025 auf der ESMO-Website veröffentlicht, der Kongress findet vom 17. bis 21. Oktober 2025 statt.
- None.
- None.
PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces two clinical data poster presentations at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place October 17 – 21 in Berlin, Germany.
The titles of the poster presentations are listed below.
#8212: Phase III Pivotal Trial of Bria-IMT + CPI vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)
#3928: Feasibility and Biomarker Validation of an International Randomized Phase 3 Trial of Bria-IMT Cell Therapy in Late Stage MBC (BRIA-ABC)
Abstracts will be published online via the ESMO website at 00:05 CEST on October 13th 2025 (6:05 pm ET on October 12th).
Following the presentations, copies of the presentations will be posted on https://briacell.com/scientific-publications/.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell presenting clinical data presentations at the ESMO Congress 2025; and the contents of all such presentations are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
FAQ
When will BriaCell (BCTX) present at ESMO 2025?
What clinical trials will BriaCell (BCTX) present data on at ESMO 2025?
Where can investors find BriaCell's ESMO 2025 presentations?
When will the ESMO 2025 abstracts for BriaCell (BCTX) be published?
